- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03073603
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) (DISCOMS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants will be randomized (1:1) to one of two groups. One group will stay on their current MS medication (Continue group), and one group will discontinue their medication (Discontinue group). They will also have some extra assessments done at their regular routine MS clinic appointment and every 6 months for the next 18-24 months. The following items will be done in addition to any assessments or procedures they are already having done as part of their clinical care:
- Questionnaires about the participant's quality of life including questions about health, mood, thinking, and social life
- Questionnaires about the participant's MS symptoms
- Test of the participant's attention, concentration, and thinking
- Test of the participant's physical symptoms
- In addition to any MRIs the participants may get as part of their routine care, they will also have an MRI 6 months from their enrollment into the study.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Denver - Anschutz Medical Campus
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Kansas
-
Kansas City, Kansas, United States, 66103
- University of Kansas Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63139
- Washington University St. Louis
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Medical Center
-
New York, New York, United States, 10029
- Mt. Sinai University
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Columbus, Ohio, United States, 43221
- The Ohio State University
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, United States, 37215
- Vanderbilt University
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia
-
-
Washington
-
Seattle, Washington, United States, 98122
- Swedish Health Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with either Relapsing-remitting MS (RRMS), Secondary progressive MS (SPMS), or Primary progressive MS (PPMS) by McDonald 2010 criteria.
- Patients defined by subtype based on 2013 updated phenotypic criteria.
Progression of MS defined by the local PI either:
- prospectively with an EDSS change of at least 1.0 points over the last two years, or
- retrospectively, with any significant change in motor function over at least one year, unrelated to relapse.
- 55 years of age or older at time of randomization;
- No evidence of recent new inflammatory disease activity (inactive by the Lublin criteria16) with no new relapse for at least five years and no new MRI lesion for at least three years
Using any of the FDA-approved MS DMTs (to include:
- interferon β-1a,
- interferon β-1b,
- glatiramer acetate,
- natalizumab,
- fingolimod,
- dimethyl fumarate,
- ocrelizumab, or
- teriflunomide; continuously for no less than 5 years.
- Taking most recent DMT continuously* for no less than two years.
- Willing to be randomized per this protocol; each patient will be questioned as to their willingness to stay in the trial regardless of the group to which group they are randomized.
- Willing to follow the protocol
Able to undergo a brain MRI without anesthesia
- Continuously will be defined as no less than 75% of all prescribed doses, with no time of greater than four weeks from last intended dose to have missed a dose (8 weeks for natalizumab, i.e. one missed dose).
Exclusion Criteria:
- Any MS relapse in the last five years, as determined at the screen visit by the PI
- Any new or definitely enlarging T2/FLAIR lesion or new gadolinium-enhancing lesion within the past three years (at least two scans separated by at least three years must be reviewed) on brain or spine MRI scan. Lesions must be 3mm or larger to be exclusionary.
- Significant (as defined by the PI) intolerance of presently-used DMT
More than two courses of acute, systemic (IV or oral) steroids in the last 5 years or any use within the last year. Course is defined as three or more days continuously, and not to exceed 14 days. No use of chronic, systemic steroids, defined as 15 or more days, in the last 5 years. Any use of steroids to treat MS relapse, possible relapse, or pseudo-relapse in the last 5 years.
- Use of inhaled or topical steroids are not an exclusion criteria.
- Use of oral steroids for no greater than 14 days given for a non-MS condition is not exclusionary.
Prior use of the following in the past 5 years:
- alemtuzumab,
- mitoxantrone,
- cyclophosphamide,
- methotrexate,
- cyclosporine,
- rituximab,
- siponimod, or
- cladribine
- Prior use of any experimental agent used as a DMT for MS in the last five years
Other significant medical or psychiatric illness, if uncontrolled. Examples:
- uncontrolled hypertension,
- uncontrolled diabetes,
- uncontrolled asthma, or
- uncontrolled depression
- Cancers other than basal cell skin cancers within the last 5 years
- Unable to give informed consent or follow the protocol
- Unable to undergo brain MRI
- Unwilling to be randomized per this protocol
- History of other chronic neurological illnesses that might mimic MS with chronic or intermittent symptoms (i.e. ALS, myasthenia gravis, chronic neuropathy, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Drug Continuation Arm
Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes.
DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
|
Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes.
DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
|
Experimental: Drug Discontinuation Arm
Participants who will discontinue their Disease Modifying Therapies (DMTs).
No other changes to their treatment occur.
DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
|
Participants who will discontinue their current MS drug.
No other changes to their treatment occur.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Developing a New MS Relapse and/or MRI Brain Lesion Over the Course of the Study Duration
Time Frame: 18-24 months, based on time of enrollment
|
The outcome is the proportion of participants in each group developing a new MS relapse and/or MRI brain lesion over the course of the study duration.
Count of Participants with either a new MS relapse and/or a new brain MRI lesion is reported.
|
18-24 months, based on time of enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number With Disability Progression Confirmed at 6 Months Using the Expanded Disability Status Scale (EDSS)
Time Frame: Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment.
|
The EDSS is a neurological examination performed by a blinded rater.
This assessment is collected at each study visit.
Increase in the EDSS score shows disease activity or progression, and must be observed six months later to be confirmed.
Whether a confirmed change is significant depends on the subject's EDSS at baseline: for those with a baseline EDSS of 5.5 points or fewer, the increase must be at least one point to be significant; for those with a baseline EDSS of 6.0 points or greater, a change of at least 0.5 points is considered significant.
We will calculate the percentage in each group of those who had a significant change at anytime during the follow-up period, which was then confirmed at 6 months later.
|
Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment.
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Upper Extremity Function
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Lower Extremity Function
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Fatigue
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Sleep Disturbance
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- General Concerns
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Executive Function
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Communication
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Anxiety
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Depression
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Positive Affect and Well-Being
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Emotional-Behavioral Dyscontrol
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Satisfaction With Social Roles and Activities
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in Neuro-QoL (Quality of Life) Short Form Scores -- Ability to Participate in Social Roles and Activities
Time Frame: Baseline, 18-24 Months, based on time of enrollment
|
The Neuro-QOL Adult PRO short form measures are collected to evaluate self-reported overall quality of life and functioning in patients with a variety of neurological conditions including MS.
The Neuro-Qol short form scales consist of 5-9 single scale item scales.
Raw scores are then converted to a standardized score with mean 50 and standard deviation 10.
The Neuro-QoL short forms used in this study with higher scores representing better outcomes are: Upper Extremity Function, Lower Extremity Function, Cognitive -- General Concerns, Cognitive -- Executive Function, Communication, Positive Affect and Well-Being, Satisfaction with Social Roles and Activities, and Ability to Participate in Social Roles and Activities.
The short forms used with lower scores representing better outcomes are: Fatigue, Sleep Disturbance, Anxiety, Depression, and Emotional-Behavioral Dyscontrol.
|
Baseline, 18-24 Months, based on time of enrollment
|
Change in SymptoMScreen Composite Score (SymptoMScreen - Overall Symptom Severity).
Time Frame: Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment. The change between baseline and Month 18-24 is reported.
|
SymptoMScreen will be collected to assess overall symptom severity.
Participants self-report across multiple neurological domains (mobility, hand function, spasticity, pain, sensory, bladder, fatigue, vision, dizziness, cognition, depression, and anxiety).
This scale is a single page, validated measure that allows for quick assessment of multiple symptoms.
Single item scores are rated as 0-6 with higher numbers representing increased limitations and symptom severity.
Composite score is calculated by summing the single item scores with total score ranges from 0 to 72.
|
Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment. The change between baseline and Month 18-24 is reported.
|
Change in Patient-Determined Disease Steps (PDDS - Disability).
Time Frame: Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment. The change between baseline and Month 18-24 is reported.
|
Patient-Determined Disease Steps will be collected to assess changes in disability from the patient's perspective.
This outcome measure is a single question.
The scores range from 0 to 8, and a participant with a low score has less perceived disability than a participant with a higher score.
|
Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment. The change between baseline and Month 18-24 is reported.
|
Change in Symbol Digit Modalities Test (SDMT - Cognition).
Time Frame: Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment. The change between baseline and Month 18-24 is reported.
|
The SDMT measures patient attention, concentration, and speed of information processing and has been validated for discriminating patients from controls.
Possible scores range from 0 to 110, with higher scores indicating a better outcome.
|
Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment. The change between baseline and Month 18-24 is reported.
|
Evaluation of the Patient's Quality of Life Using the MSIS-29 Scale -- Physical Impact
Time Frame: Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment. The change between baseline and Month 18-24 is reported.
|
The Multiple Sclerosis Impact Scale (MSIS-29) will be collected to assess changes in quality of life from the patient's perspective.
The MSIS has 29 questions.
Each question asks the participant to rank how impacted they are in a certain aspect of their life.
The options are 1 through 4. 1 indicates not at all impacted while 4 indicates extremely impacted.
The lower the final score, the less impacted the participant is overall.
Scores on the physical impact scale range from 20-80 and from 9-36 on the psychological impact scale.
We will compare the proportion in each group who have had a change of 7.5 points or more (considered a clinically meaningful change).
|
Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment. The change between baseline and Month 18-24 is reported.
|
Evaluation of the Patient's Quality of Life Using the MSIS-29 Scale -- Psychological Impact
Time Frame: Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment. The change between baseline and Month 18-24 is reported.
|
The Multiple Sclerosis Impact Scale (MSIS-29) will be collected to assess changes in quality of life from the patient's perspective.
The MSIS has 29 questions.
Each question asks the participant to rank how impacted they are in a certain aspect of their life.
The options are 1 through 4. 1 indicates not at all impacted while 4 indicates extremely impacted.
The lower the final score, the less impacted the participant is overall.
Scores on the physical impact scale range from 20-80 and from 9-36 on the psychological impact scale.
We will compare the proportion in each group who have had a change of 7.5 points or more (considered a clinically meaningful change).
|
Baseline, then every 6 months for up to a maximum of 24 months, based on time of enrollment. The change between baseline and Month 18-24 is reported.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Number of New T2 Lesions on MRI
Time Frame: Baseline, then every 6 months for 2 years with one exception at 18 months.
|
MRIs will be reviewed to determine the total number of new T2 lesions that develop for each subject over the course of the study.
Lesion counts will be performed by the central MRI facility.
|
Baseline, then every 6 months for 2 years with one exception at 18 months.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John Corboy, MD, University of Colorado, Denver
Publications and helpful links
General Publications
- Hartung HP, Meuth SG, Miller DM, Comi G. Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis. Curr Opin Neurol. 2021 Aug 1;34(4):598-603. doi: 10.1097/WCO.0000000000000960.
- McGinley MP, Cola PA, Fox RJ, Cohen JA, Corboy JJ, Miller D. Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. Mult Scler. 2020 Oct;26(12):1581-1589. doi: 10.1177/1352458519867314. Epub 2019 Aug 1.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-2388
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
Clinical Trials on Standard of Care
-
brett rasmussenCompleted
-
Johns Hopkins UniversityRecruitingCompartment Syndrome of Leg | Extracorporeal Membrane Oxygenation Complication | Limb Ischemia, Critical | Limb IschemiaUnited States
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
Aventusoft, LLC.National Heart, Lung, and Blood Institute (NHLBI); Cleveland Clinic FloridaRecruitingHeart Failure (HF)United States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedSevere COVID-19Israel
-
Ruijin HospitalRecruitingCOVID-19 PneumoniaChina
-
Institut Claudius RegaudCompletedMETASTATIC CANCERFrance
-
Ziv HospitalNot yet recruiting
-
Hofseth Biocare ASAKGK Science Inc.CompletedCovid-19 | COVIDCanada, Brazil, Hungary, Mexico, Serbia
-
City University of New York, School of Public HealthNew York State Psychiatric Institute; University of KwaZulu; International Initiative... and other collaboratorsCompleted